Table 2 ACR20, 50, and 70 responses between treatment groups at weeks 12 and 24
ITT analysis | PP analysis | |||
|---|---|---|---|---|
Test (n = 112) | Reference (n = 56) | Test (n = 107) | Reference (n = 52) | |
At Week 12 | ||||
ACR20 response (%) | 108 (96.43) | 54 (96.43) | 107 (100) | 52 (100) |
PD (95% CI) | 0.0 (−6.0, 6.0) | 0.0 (− 0.03, 0.07) | ||
p value | 1.000 | 1.000 | ||
ACR50 response (%) | 27 (24.11) | 20 (35.71) | 26 (24.30) | 19 (36.54) |
PD (95% CI) | − 11.6 (− 26.4, 3.2) | −12.2 (− 27.6, 3.2) | ||
p value | 0.145 | 0.134 | ||
ACR70 response (%) | 6 (5.36) | 6 (10.71) | 6 (5.61) | 6 (11.54) |
PD (95% CI) | −5.4 (−14.5, 3.8) | −5.9 (− 15.6, 3.8) | ||
p value | 0.217 | 0.209 | ||
At Week 24 | ||||
ACR20 response (%) | 104 (92.86) | 54 (96.43) | 99 (96.12) | 51 (100.00) |
PD (95% CI) | −3.6 (−10.4, 3.2) | −3.9 (−7.6, 0.2) | ||
p value | 0.499 | 0.303 | ||
ACR50 response (%) | 89 (79.46) | 44 (78.57) | 86 (83.50) | 42 (82.35) |
PD (95% CI) | 0.9 (−12.2, 14.0) | 1.1 (−11.5, 13.8) | ||
p value | 1.000 | 1.000 | ||
ACR70 response (%) | 54 (48.21) | 30 (53.57) | 53 (51.46) | 29 (56.86) |
PD (95% CI) | −5.4 (−21.4, 10.7) | −5.4 (−22.1, 11.3) | ||
p value | 0.624 | 0.608 | ||